Precision Frontiers in Mantle Cell Lymphoma: Tailored Therapies and Emerging Innovations
Apeksha Dasharath Rajguru *
SEF’s Suryadatta College of Pharmacy Healthcare and Research, Maharashtra, India.
Anuprita Tejesh Kamble
SEF’s Suryadatta College of Pharmacy Healthcare and Research, Maharashtra, India.
Akshada Devendra Khetre
Dnyan Ganga College of Pharmacy Thane, Maharashtra, India.
Falgunee Dasharath Ghadi
Lokmanya Tilak Institute of Pharmacy Mumbai, Maharashtra, India.
*Author to whom correspondence should be addressed.
Abstract
Introduction: Mantle cell lymphoma (MCL) is a rare and aggressive form of B-cell non-Hodgkin lymphoma, representing 5%-7% of cases, with a median age at diagnosis around 65 years. Historically, MCL was considered incurable, with chemotherapy offering only temporary remission. Recent advancements in targeted therapies have transformed the treatment landscape, providing better progression-free survival (PFS) and improved quality of life. Despite these innovations, MCL's heterogeneity and high-risk subtypes present ongoing challenges in achieving long-term remission.
Methodology: This review summarizes current research on the molecular pathogenesis, prognostic markers, and treatment options for MCL. We explore genetic abnormalities, such as the t(11;14)(q13;q32) translocation and TP53 mutations, and their impact on prognosis. We also evaluate established and emerging biomarkers, including the Ki-67 proliferation index and minimal residual disease (MRD) monitoring, as tools to tailor therapy. Treatment strategies are examined, focusing on the evolution from chemotherapy to targeted agents like Bruton's tyrosine kinase inhibitors.
Results: Recent studies highlight the role of genetic markers like cyclin D1 overexpression and TP53 mutations in driving MCL's aggressive course. Prognostic tools like the Mantle Cell Lymphoma International Prognostic Index (MIPI) and Ki-67 index are pivotal in patient stratification, guiding therapy choices. First-line treatment regimens, such as R-hyperCVAD and R-DHAP, show improved outcomes, especially when combined with autologous stem cell transplantation (ASCT). New targeted therapies, such as BTK inhibitors, BCL-2 antagonists, and cellular therapies, have shown promising results in clinical trials.
Conclusion: The treatment landscape of MCL has evolved significantly, with tailored therapies offering better outcomes. Continued research into molecular biomarkers and treatment combinations will refine management strategies and provide further improvements in survival and quality of life for MCL patients. A personalized, precision-based approach remains essential in optimizing care for this challenging malignancy.
Keywords: Mantle cell lymphoma, targeted therapy, BTK inhibitors, Cyclin D1, TP53 mutation, Ki-67, MIPI, minimal residual disease, autologous stem cell transplantation, personalized medicine